| Name | Linagliptin |
| Classes |
Antidiabetic Agent Metabolic Agent |
| Diseases |
Type 2 Diabetes Mellitus Hormonal Disorder |
Bangla
EnglishLinagliptin
Linagliptin is an oral hypoglycemic medication. It belongs to a class of hypoglycemics called the Dipeptidyl Peptidase 4 inhibitors (DPP4). DPP4 is an enzyme that metabolizes Glucagon like peptide, which is an incretin. So, DPP4 inhibitors work by increasing the concentration of incretins in the blood which ultimately results in the increased secretion of insulin.
Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The recommended dose of Linagliptin is 5 mg once daily. Linagliptin can be taken with or without food
Side effects reported with use of linagliptin are as follows-
- hypoglycemia
- upper respiratory tract infection
- nasopharyngitis
- headache
- When Linagliptin is combined with an insulin secretagogue (e.g., sulfonylurea) or insulin therapy, the risk of hypoglycemia increases. To reduce the risk of hypoglycemia, consider lowering the dose of the sulfonylurea or insulin.
- There have been no clinical studies that show conclusive evidence of Linagliptin or any other anti-diabetic drug lowering macrovascular risk.
Contraindication
Contraindicated in patients hypersensitive to Linagliptin or similar drugs such as-
None known.
None known.